Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer

  • Authors:
    • Ho Won Kang
    • Sung Pil Seo
    • Pildu Jeong
    • Yun‑Sok Ha
    • Won Tae Kim
    • Yong‑June Kim
    • Sang‑Cheol Lee
    • Seok‑Joong Yun
    • Wun‑Jae Kim
  • View Affiliations

  • Published online on: June 19, 2017     https://doi.org/10.3892/ol.2017.6408
  • Pages:2468-2474
0

Abstract

Our previous study reported a clinically applicable prognostic gene classifier for primary non‑muscle-invasive bladder cancer (NMIBC). The present study aimed to perform long‑term validation of this classifier in the prediction of muscle-invasive disease. Previously published gene expression profiles were used from 176 patients with NMIBC with extended follow‑up. Progression was defined as development of muscle invasion or metastasis, and the progression risk score was calculated using the previously developed eight‑gene progression classifier. During median follow‑up of 72.8 (interquartile range, 37.0‑118.7) months, 26 (14.8%) patients progressed to muscle‑invasive bladder cancer. The molecular progression risk score was significantly associated with clinicopathological variables, including tumor number, stage, grade and multivariate risk assessment tools (P<0.05 in each case). Multivariate Cox regression analysis revealed that molecular progression risk score was an independent predictor of development of invasive tumor, either as a continuous variable [hazard ratio (HR), 1.489; 95% confidence interval (CI), 1.216‑1.823; P<0.001] or as a categorical variable (HR, 5.026; 95% CI, 1.619‑15.608; P=0.005). In conclusion, the present results confirmed the clinical utility of the progression‑associated gene classifier for prediction of development of muscle invasion in NMIBC. The molecular progression risk score may aid in selecting patients who could benefit from more aggressive therapeutic intervention.

Related Articles

Journal Cover

August 2017
Volume 14 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kang, H.W., Seo, S.P., Jeong, P., Ha, Y., Kim, W.T., Kim, Y. ... Kim, W. (2017). Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer. Oncology Letters, 14, 2468-2474. https://doi.org/10.3892/ol.2017.6408
MLA
Kang, H. W., Seo, S. P., Jeong, P., Ha, Y., Kim, W. T., Kim, Y., Lee, S., Yun, S., Kim, W."Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer". Oncology Letters 14.2 (2017): 2468-2474.
Chicago
Kang, H. W., Seo, S. P., Jeong, P., Ha, Y., Kim, W. T., Kim, Y., Lee, S., Yun, S., Kim, W."Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer". Oncology Letters 14, no. 2 (2017): 2468-2474. https://doi.org/10.3892/ol.2017.6408